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Objective: The diagnosis of mild cognitive impairment (MCI) and dementia requires detailed
neuropsychological examinations. These examinations typically yield a large number of outcome
variables, which may complicate the interpretation and communication of results. The purposes of
this study were the following: (i) to reduce a large data set of interrelated neuropsychological variables
to a smaller number of cognitive dimensions; (ii) to create a common metric for these dimensions
(z-scores); and (iii) to study the ability of the cognitive dimensions to distinguish between groups of
patients with different types of cognitive impairment.
Methods:We tested 1646 patients with different forms of dementia or with a major depression with
a standard (n= 632) or, if cognitively less affected, a challenging neuropsychological battery
(n= 1014). To identify the underlying cognitive dimensions of the two test batteries, maximum
likelihood factor analyses with a promax rotation were conducted. To interpret the sum scores of
the factors as standard scores, we divided them by the standard deviation of a cognitively healthy
sample (n= 1145).
Results: The factor analyses yielded seven factors for each test battery. The cognitive dimensions in
both test batteries distinguished patients with different forms of dementia (MCI, Alzheimer’s
dementia or frontotemporal dementia) and patients with major depression. Furthermore, patients
with stable MCI could be separated from patients with progressing MCI. Discriminant analyses with
an independent new sample of patients (n=306) revealed that the new dimension scores distinguished
new samples of patients with MCI from patients with Alzheimer’s dementia with high accuracy.
Conclusion: These findings suggest that these cognitive dimensions may benefit neuropsychological
diagnostics.# 2013 The Authors International Journal of Geriatric Psychiatry Published by John Wiley
& Sons Ltd.
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Introduction
Diagnoses of mild cognitive impairment (MCI) and
dementia require detailed neuropsychological examina-
tions (Dubois et al., 2007; Albert et al., 2011; McKhann
et al., 2011; www.dsm5.org). Thus, it is critical that
clinicians conduct comprehensive neuropsychological
assessments examining a wide range of cognitive
domains. To efficiently understand and communicate
the multiplicity of outcome variables generated
from neuropsychological test batteries, several investiga-
tors have created single summary or composite
scores (Alzheimer’s Disease Assessment Scale-cognitive
subscale (ADAS-Cog) score; Rosen et al., 1984), different
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neuropsychological test battery (NTB) composite
scores; e.g., Harrison et al., 2007; Lannfelt et al.,
2008; Vellas et al., 2009) or the Consortium to
Establish a Registry for Alzheimer’s Disease (CERAD)
total score (Ehrensperger et al., 2010). However, the
use of single metacognitive summary scores dilutes
potentially important differential contributions from
different neuropsychological domains and may overlook
treatment responses in specific cognitive domains. In an
ideal clinical and research world, a neuropsychological
test battery would produce one single, well-interpretable
outcome score per cognitive domain, which would
enable quantification of the extent of impairment in
each domain and—at the same time—provide a
cognitive profile of the patient’s performance, which aids
the identification of the underlying cause.
The aims of the present study were the following:
(i) to reduce a data set of interrelated neuropsycholog-
ical variables to a small number of interpretable
cognitive dimensions; (ii) to create z-scores for these
dimensions to equate the metric across the dimen-
sions; and (iii) to determine the ability of these new
cognitive dimension z-scores to distinguish between
groups of patients with different types of cognitive
impairment, that is, MCI, Alzheimer’s dementia (AD),
frontotemporal dementia (FTD) and cognitive
impairment in individuals with major depression. We
chose these diagnostic groups as the neuropsychological
literature attests to the difficulty of distinguishing
patients with MCI from those with AD (De Jager
et al., 2003; Lambon Ralph et al., 2003) and depressed
patients from patients with MCI or AD (Gianotti and
Marra, 1994; Christensen et al., 1997; Künig et al.,
2006) or patients with AD from patients with FTD
(Perry and Hodges, 2000; Levy and Chelune, 2007;
Rascovsky et al., 2007) on the basis of neuropsycholog-
ical tests. A secondary analysis aimed to address the
stability of the cognitive domain profiles with discrimi-
nant function analyses with a new sample of patients.
Methods
Participants
All participants were outpatients from theMemory Clinic,
Department of Geriatrics, University Hospital Basel,
Switzerland, who were examined between 2006 and 2011.
The multidisciplinary assessment included the
following: (i) independent, detailed clinical interviews
with the patient and (where possible) informant
formally assessing the patients’ mood and cognitive
and everyday functioning; (ii) thorough medical
examinations including neurological status; (iii) a
magnetic resonance imaging examination with sequences
optimized to detect structural brain abnormalities
associated with cognitive impairment; (iv) a complete
laboratory workup; (v) one of two comprehensive neuro-
psychological test batteries assessing the patients’ cogni-
tive functioning. Thereby, the challenging battery was
used for higher functioning patients and the standard bat-
tery for more impaired patients (refer to the decision tree
in the Supplementary Material). These two test batteries
differ primarily in terms of the instruments assessing
verbal and visual episodic memories (Table 1). A
detailed description of each test in the two neuropsycho-
logical assessment batteries is provided as Supplementary
Material.
Diagnoses were established at an interdisciplinary
diagnosis conference with geriatricians, neurologists,
neuropsychologists, a neuropathologist, neuroimaging
experts and psychiatrists. Because the neuropsycho-
logical data were available at the diagnosis conference,
the question of circularity arises. However, diagnoses
were never based on the neuropsychological assess-
ment alone but rather on the integration of all com-
prehensive multidisciplinary findings. Nevertheless, it
is not possible to completely rule out the possibility
that the reported sensitivities and specificities were
artificially inflated by the availability of the neuropsy-
chological data at the diagnosis conference.
Six hundred and thirty-two patients received the
standard battery, and 1014 cognitively less affected
patients were administered the challenging battery.
The demographic characteristics, mini mental status
examination (Folstein et al., 1975) scores and
diagnosis of the two patient groups are shown in
Table 2A. The two patient groups differed significantly
with respect to age (p< 0.001) and mini mental status
examination score (p< 0.001).
Clinical diagnoses were made according to the
following criteria. MCI was diagnosed according to
the Winblad et al. (2004) criteria. Probable AD
(probable AD) was diagnosed according to the criteria
outlined by the National Institute for Neurological and
CommunicativeDisorders and Stroke and theAlzheimer’s
Disease and Related Disorders Association (NINCDS-
ADRDA; McKhann et al., 1984) and DSM-IV (American
Psychiatric Association, 1994) criteria for AD. Probable
vascular dementia was diagnosed according to the criteria
outlined by the National Institute of Neurological
Disorders and Stroke and the Association Internationale
pour la Recherche et l’Enseignement en Neurosciences
(Romàn et al., 1993). FTD was diagnosed according to
the Neary et al. (1998) criteria, and major depression
was diagnosed according to theDSM-IV criteria (American
Psychiatric Association, 1994). Patients with a diagnosis
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of mixed dementia fulfilled two or more sets of
diagnostic criteria for dementia listed in the previous texts.
Depression was assessed with two different
questionnaires: the Geriatric Depression Scale; Sheikh
and Yesavage, 1986) was used in the standard battery
and the Beck Depression Inventory (Beck et al.,
1961) was administered in the challenging battery.
This retrospective data analysis was approved by the
Ethics Committee of Basel, Switzerland.
Statistical analyses
On the basis of the methodology described by Berres
and colleagues (2000; refer also to Berres et al.,
2008), the raw scores on all neuropsychological test
results from all patients were transformed into
demographically adjusted z-scores.
Many patients had missing values in the Trail
Making Test A (TMT A) (i.e., required more than
180 s to complete the task; n= 12/1646; 0.73%) and
the TMT B (TMT B) (i.e., required more than 300 s
to complete the task; n= 214/1646; 13.0%). To be able
to use the TMT data in our analyses, missing values on
this test were replaced by applying a malus to a fictive
z-score on TMT A or TMT B. In order to create a
malus for TMT B, we focused on two subsets of
demented subjects: (i) patients who completed TMT
B in the time interval between 240 and 300 s; and (ii)
patients who failed to complete the TMT B. We aimed
to compare their respective sample means in a
representative score for test performance, namely,
the z-values of the CERAD total score (Ehrensperger
et al., 2010). Subset (i) achieved a mean CERAD total
score of 2.41, whereas subset (ii) achieved a mean
CERAD total score of 3.24. The resulting difference
of 0.83 is a possible malus that could be subtracted from
the minimal z-score from the TMT B (300 s) for each
participant who failed to complete this test. This same
procedure was applied for the interval between 270
and 300 s (reduced subset (i), mean=2.54), with a
possible malus of 0.7. We decided to subtract a malus
of 0.7 from the z-scores of each patient who scored
300 on the TMT B. This procedure ensures an individ-
ual, demographically adjusted penalty for patients who
failed to complete the test. The same procedure was
carried out for TMT A, resulting in a malus of 0.4.
We selected 18 measures from each test battery,
which represented a comprehensive estimate of
cognitive functions most likely to be affected in
dementia (Table 1). The z-scores of all selected variables
fulfilled the requirements for normal distributions.
To identify the underlying factor structure in the
two test batteries, the z-scores of the 18 variables of
interest from each test battery (corresponding to the
study samples described in Table 2A) were entered
into two independent maximum likelihood factor
analyses with promax rotation. The promax rotation
was used because we assumed that underlying cogni-
tive dimensions were correlated. Those z-scores that
loaded highly on a common factor were summed to
form a cognitive dimension. Beforehand, we con-
firmed that the sum of these z-scores was highly corre-
lated with the corresponding factor scores. Because in
a cognitively healthy population the standard devia-
tion of a sum of z-scores is usually different from 1,
the z-score for each factor was standardized on the ba-
sis of an independent sample of healthy individuals
(refer to Berres et al., 2000). This independent sample
was a subsample of the healthy participants of the
BAsel Study on the ELderly (BASEL; Monsch et al.,
2000) cohort. BASEL participants had also been ad-
ministered either the standard or the challenging
Table 1 The two neuropsychological test batteries used in the Memory
Clinic Basel and the 18 variables of interest
Standard battery Challenging battery
1 WMS-R—verbal digit span,
forward
WMS-R—verbal digit span,
forward
2 WMS-R—verbal digit span,
backward
WMS-R—verbal digit span,
backward
3 WMS-R—Corsi block,
forward
WMS-R—Corsi block,
forward
4 WMS-R—Corsi block,
backward
WMS-R—Corsi block,
backward
5 CERAD-NABWord List,
learning
CVLT, learning
6 CERAD-NABWord List,
delayed recall
CVLT, long delay free recall
7 CERAD-NAB word list,
recognition
CVLT, recognition
8 CERAD-NABWord List,
intrusions
CVLT, free recall intrusions
9 CERAD-NAB figures, copy Rey-figure, copy
10 CERAD-NAB figures,
delayed recall
Rey-figure, delayed recall
11 Animal fluency Animal fluency
12 S-words S-words
13 BNT (15 items) BNT (15 items)
14 TMT A TMT A
15 TMT B TMT B
16 Five-Point Test Five-Point Test
17 Stroop, card 1 Stroop, card 1
18 Stroop, card 3/1 Stroop, card 3/1
WMS-R, Wechsler Memory Scale-Revised (Wechsler, 1987);
CERAD-NAB, Consortium to Establish a Registry for Alzheimer’s
Disease–Neuropsychological Assessment Battery (Morris et al.,
1988); CVLT, California Verbal Learning Test (Delis et al., 1987);
Rey-figure, Rey–Osterrieth Complex Figure Test (Rey, 1941); Animal
fluency (Isaacs and Kennie, 1973); S-words (Spreen and Benton,
1977); BNT, Boston Naming Test (Kaplan et al., 1983); Trial Making
Test A +B, TMT A and TMT B (Spreen and Strauss, 1991); Five-
Point Test (Regard et al., 1982); Stroop Test (Stroop, 1935).
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battery (Table 2B). The dimension score including the
Five-Point Test (Regard et al., 1982) was standardized
with only 282 independent participants who had com-
pleted the standard battery and 277 independent par-
ticipants who had completed the challenging battery
sample, because this test was only introduced later
during the course of the BASEL Study. All other di-
mensions scores were standardized with 590 (standard
battery) or 555 (challenging battery) independent,
cognitively healthy participants.
To examine how well the new dimension scores
distinguished different diagnostic groups, the dimen-
sion scores were tested with the different diagnostic
groups used to calculate the dimensions using the
Kruskal–Wallis test. We compared patients from the
following four diagnostic groups with each other:
MCI, AD, FTD and major depression. In the standard
battery, the small size of the sample of patients with
major depression (only nine patients; Table 2A) pre-
cluded such comparisons; therefore, we only com-
pared patients with MCI, AD and FTD with each
other. Only five patients with a FTD had completed
the challenging battery (refer also to Table 2A). Thus,
on the challenging battery, we only compared patients
with MCI, AD and major depression with each other.
Because only three groups were tested with each battery,
Mann–Whitney U-tests could be used for post-hoc
comparisons without adjustment of α by applying a
closed testing procedure. These analyses were followed
up with linear discriminant analyses of the seven di-
mension scores in the four diagnostic groups (MCI,
AD, FTD or major depression). Discriminant analysis
allocates an observed vector x to group i, if
di ¼ x mið ÞTS1 x–mið Þ
¼ minj¼1;…;4 x mj
 T
S1 x–mj
 
;
where mj is the mean vector for group j and S is the
within group covariance matrix. Because the likelihood
of x belonging to group i is proportional to exp(di),
the posterior probabilities can be computed by Bayes’
formula as
P

group ijxÞ ¼ pie
di=2
p1e
d1=2 þ p2ed2=2 þ p3ed3=2 þ p4ed4=2
This is the probability that a patient with dimension
score x belongs to group i.
Discriminant analyses were conducted for each test
battery. Patients were allocated to the diagnostic
groups according to the aforementioned rule, which
is equivalent to allocating to a group with the highest
posterior probability. This allocation is correlated with
the correct diagnostic group (i.e., MCI, AD, FTD or
major depression).
The classification results from these analyses were
tested with a new validation sample of 306 patients
who had been examined at the Memory Clinic Basel
between August 2011 and August 2012 (Table 2C).
This sample only contains data from patients who
had received a diagnosis of MCI, AD, FTD or major
depression and from whom all data were available.
We also conducted a discriminant function analysis
to calculate each individual’s probability to be classi-
fied in one of the four diagnostic groups, and the
diagnosis with the highest probability was compared
with the diagnosis made in the Memory Clinic.
Table 2B Demographic characteristics of the different study samples:
normative study sample (NC) (n = 1145)
Standard battery Challenging battery
N 590 555
Gender, males (%) 52 45.4
Age±SD (y) 68.65±7.66 68.32±7.61
Education±SD (y) 12.34±2.98 12.34±3.00
MMSE±SD 28.88±1.13 28.92±1.10
SD, standard deviation; MMSE, mini mental status examination
(Folstein et al., 1975); NC, normal controls.
Table 2A Demographic characteristics of the different study samples:
Memory Clinic study sample (n = 1646)
Standard
battery
Challenging
battery
N 632 1014
Gender, males (%) 45.4 58.4
Age±SD (y) 74.56±7.91 65.42±9.77
Education ±SD (y) 11.36±2.92 13.21±2.90
MMSE±SD 25.28±2.38 28.56±1.31
Probable AD 241 90
MCI 215 468
Amnestic MCI,
single domain
18 89
Amnestic MCI,
multiple domains
100 178
Nonamnestic MCI,
single domain
34 117
Nonamnestic MCI,
multiple domains
63 84
FTD 14 5
Major depression 9 75
No cognitive impairment 18 218
Mixed dementia 34 5
Probable VAD 16 8
Other diagnoses 85 145
SD, standard deviation; MMSE, mini mental status examination
(Folstein et al., 1975);MCI,mild cognitive impairment; AD, Alzheimer’s
dementia; VAD, vascular dementia; FTD, frontotemporal dementia.
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Results
In the standard battery, the maximum likelihood
factor analysis with promax rotation yielded seven
factors (p= 0.142 for the null hypothesis that seven
factors are sufficient). The structure of the factor
analysis is shown in the matrix of factor loadings in
Table 3A. This seven factors solution explained
47.2% of the variance.
In the challenging battery, the maximum likelihood
factor analysis with promax rotation yielded nine
factors (p= 0.141 for the null hypotheses that nine
factors are sufficient). However, this solution revealed
that four factors included only one variable each. This
is undesirable because the goal of the factor analysis is
to reduce the variables with the factors, and, as
Harman (1976) pointed out, a law or model should
be simpler than the data upon which it is based. The
factor analysis with eight factors revealed a similar
problem: it yielded a factor solution with two factors
including only one variable each. Furthermore, the
p-value of the eight-factor solution (p= 0.038 for the
null hypothesis that eight factors are sufficient)
showed that the data would be better explained with
more factors. The factor analysis with seven factors
had a p< 0.0001 (for the null hypotheses that seven
factors are sufficient) suggesting that, also in this case,
the data would be better explained by a greater
number of factors. However, the seven-factor solution
appears clinically best interpretable (Table 3B), and it
corresponds closely to the seven factors of the
standard battery. This seven factors solution explained
56.8% of the variance.
Table 2C Demographic characteristics of the different study samples:
Memory Clinic validation sample (n = 306)
Standard battery Challenging battery
N 151 155
Gender, males (%) 44.4 58.0
Age±SD (y) 75.5± 7.33 68.0 ± 9.8
Education ±SD (y) 11.54±3.17 13.2± 2.83
MMSE±SD 23.11±4.28 28.03±2.60
Probable AD 94 24
MCI 50 118
FTD 3 2
Major depression 4 11
SD, standard deviation; MMSE, mini mental status examination
(Folstein et al., 1975); MCI, mild cognitive impairment; AD,
Alzheimer’s dementia; FTD, frontotemporal dementia.
Table 3A Factor loadings for a seven-factor model of the two test batteries: standard battery
Factor
Test 1 2 3 4 5 6 7
CERAD-NAB WL, learning 0.768 0.176 0.114
CERAD-NAB WL, recall 0.938 0.121
CERAD-NAB WL, recognition 0.545
TMT A 0.681 0.145
TMT B 0.795 0.109 0.112
S-words 0.107 0.148 0.552 0.115
Animal fluency 0.796 0.117
CERAD-NAB figures, recall 0.989
Stroop, card 1 0.112 0.932
WMS-R—verbal digit span
Forward 0.694
WMS-R—verbal digit span
Backward 0.591 0.104
WMS-R—Corsi block
Backward 0.118 0.597
BNT 0.100 0.122 0.495
CERAD-NAB figures, copy 0.180 0.110 0.201 0.268
WMS-R—Corsi block,
Forward 0.102 0.400
Stroop, card 3/1 0.335 0.198
Five-Point Test 0.486 0.156
CERAD-NAB WL, intrusions 0.303 0.156
CERAD-NAB, Consortium to Establish a Registry for Alzheimer’s Disease–Neuropsychological Assessment Battery (Morris et al., 1988); WMS-R,
Wechsler Memory Scale-Revised (Wechsler, 1987; BNT, Boston Naming Test (Kaplan et al., 1983); Trial Making Test A +B, TMT A and B
(Spreen and Strauss, 1991).
Loadings that indicate which variables enter dimension scores are emphasized (loadings <0.1 are suppressed and variables sorted according to
loadings >0.5).
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The seven factors were labeled according to the
cognitive functions assessed by the tests that loaded
highly on them.
To determine the final cognitive dimension scores,
the z-scores of all variables, which loaded highly on
one factor (highlighted in Table 3A and 3B), were added
and divided by the standard deviation of the cognitively
healthy sample (Table 2B). The seven cognitive
dimensions resulting from these calculations and their
corresponding z-score formulae are shown in Table 4.
Both test batteries yielded the same factor structure.
Comparisons of the seven cognitive dimensions
between the diagnostic groups revealed that some cogni-
tive dimensions from the two test batteries distinguished
between the diagnostic groups (Table 5A and 5B and
Figure 1(A)). In the standard battery, five of the seven
Table 3B Factor loadings for a seven-factor model of the two test batteries: challenging battery
Factor
Test 1 2 3 4 5 6 7
CVLT, learning 0.810 0.151
CVLT, recall 0.976
CVLT, recognition 0.745 0.106
TMT A 0.936
TMT B 0.850 0.118
S-words 0.759 0.105
Animal fluency 0.854
WMS-R—verbal digit span
Forward 0.910
WMS-R—verbal digit span
Backward 0.618
WMS-R—Corsi block
Backward 1.068
Rey-figure, recall 0.962
Stroop, card 3/1 0.119 0.128 0.755
Stroop, card 1 0.285 0.235 0.156 0.418
BNT 0.286 0.191
Rey-figure, copy 0.165 0.431
WMS-R—Corsi block
Forward 0.303 0.117 0.255
Five-Point Test 0.101 0.425 0.364
CVLT, intrusions 0.291
WMS-R, Wechsler Memory Scale-Revised (Wechsler, 1987); CVLT, California Verbal Learning Test (Delis et al., 1987); BNT, Boston Naming
Test (Kaplan et al., 1983); Trial Making Test A +B, TMT A and B (Spreen and Strauss, 1991).
Loadings that indicatewhich variables enter dimension scores are emphasized (loadings<0.1 are suppressed and variables sorted according to loadings>0.5).
Table 4 The seven cognitive dimensions and their z-scores
Cognitive dimension z-scores
1. Verbal attention (WMS-R–verbal digit span, forward+WMS-R–verbal digit span, backward)/1.86
2. Visual attention (WMS-R–Corsi block, forward+WMS-R–Corsi block, backward)/1.57
3. Verbal learning and memory Standard battery
CERAD-NAB Word List, learning+CERAD-NAB Word List, delayed recall +CERAD-NAB Word List,
recognition+CERAD-NAB Word List, intrusions)/2.86
Challenging battery
(CVLT, learning+CVLT, long delay free recall +CVLT, recognition+CVLT, free recall intrusions)/3.04
4. Visual learning and memory Standard battery
(CERAD-NAB figures, copy+CERAD-NAB figures, delayed recall)/1.72
Challenging battery
(Rey-figure, copy+Rey-figure, delayed recall)/1.64
5. Verbal language production (Animal fluency+S-words +BNT)/2.07
6. Executive motor ability (TMT A+TMT B+Five-Point Test)/2.09
7. Executive visual ability (Stroop, card 1Stroop, card 3/1)/1.68
WMS-R, Wechsler Memory Scale-Revised (Wechsler, 1987); CERAD-NAB, Consortium to Establish a Registry for Alzheimer’s Disease–
Neuropsychological Assessment Battery (Morris et al., 1988); CVLT, California Verbal Learning Test (Delis et al., 1987); BNT, Boston
Naming Test (Kaplan et al., 1983); Trial Making Test A + B, TMT A and B (Spreen and Strauss, 1991).
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cognitive dimensions distinguished significantly between
the diagnostic groups (verbal attention, verbal learning
and memory, visual learning and memory, verbal lan-
guage production and executive visual ability). Because
of the small sample size of the FTD group of patients,
the differences between the cognitive dimensions of this
group and the dimensions of the other patient groups
did not reach significance; also, the differences were
numerically large. In the challenging battery, also five of
the seven cognitive dimensions differed significantly
between patient groups (visual attention, verbal learning
and memory, visual learning and memory, verbal lan-
guage production and executive motor ability).
The diagnostic accuracies based on the cognitive
dimensions are also shown in Table 5A and 5B. Be-
cause of the small sample size of patients with de-
pression in the standard battery and of FTD
patients in the Challenging battery, we only calcu-
lated the correct classification for these patients in
one of the two batteries. The results revealed that
the cognitive dimensions are able to distinguish
between groups of patients with various types of
dementia and between patients with dementia and those
with major depression. In summary, the cognitive
dimensions in the two test batteries that distinguish best
between patients withMCI and those with AD are the two
Table 5B Cognitive dimension scores of the four diagnostic groups, post-hoc comparisons and diagnostic accuracies: challenging battery
Cognitive dimension
Major depression
(n=75)
MCI
(n=468)
Probable AD
(n=90)
p-
value
Post-hoc comparisons
(p<0.05)
Verbal attention 0.55 (1.00) 0.54 (0.88) 0.60 (0.91) 0.994 n.s.
Visual attention 0.55 (1.25) 0.66 (1.08) 1.21 (1.01) <0.001 MCI=MD>AD
Verbal learning and memory 1.19 (1.42) 1.48 (1.38) 2.89 (1.23) <0.001 MD>MCI>AD
Visual learning and memory 0.17 (1.24) 0.44 (1.13) 1.28 (1.18) <0.001 MCI=MD>AD
Verbal language production 0.44 (1.15) 0.52 (1.07) 1.19 (1.12) <0.001 MCI=MD>AD
Executive motor ability 0.85 (1.59) 0.78 (1.29) 1.72 (1.48) <0.001 MCI=MD>AD
Executive visual ability 0.09 (1.13) 0.08 (1.08) 0.24 (1.03) 0.151 n.s.
Diagnostic accuracies
Predicted diagnosis
Major depression 12 (16%) 29 (6%) 4 (4%)
MCI 60 (80%) 406 (87%) 73 (81%)
Probable AD 1 (1%) 28 (6%) 13 (14%)
AD, Alzheimer’s dementia; MCI, mild cognitive impairment; n.s., not significant.
Values are mean z-scores (standard deviation). The p-values are from the Kruskal–Wallis tests with Monte Carlo method, the post-hoc comparisons
from the Man–Whitney U-tests.
Table 5A Cognitive dimension scores of the four diagnostic groups, post-hoc comparisons and diagnostic accuracies: standard battery
Cognitive dimension MCI (n=215) Probable AD (n=241) FTD (n=14) p-value Post-hoc comparisons (p<0.05)
Verbal attention 0.86 (0.77) 0.70 (0.83) 1.09 (0.93) 0.024 MCI<ADa
Visual attention 1.11 (0.98) 1.24 (0.98) 1.05 (1.13) 0.292 n.s.
Verbal learning and memory 1.32 (1.16) 2.89 (1.02) 2.13 (1.32) <0.001 MCI>FTD=AD
Visual learning and memory 1.06 (1.05) 1.43 (0.94) 1.36 (1.09) <0.001 MCI>ADa
Verbal language production 0.89 (1.09) 1.35 (1.09) 3.18 (2.01) <0.001 MCI>AD>FTD
Executive motor ability 1.52 (1.19) 1.68 (1.18) 2.04 (1.55) 0.168 n.s.
Executive visual ability 0.13 (1.26) 0.11 (1.27) 1.07 (1.52) 0.015 MCI=AD>FTD
Diagnostic accuracies
Predicted diagnosis
MCI 158 (74%) 41 (17%) 6 (43%)
Probable AD 56 (26%) 199 (83%) 2 (14%)
FTD 1 (1%) 1 (0%) 6 (43%)
AD, Alzheimer’s dementia; MCI, mild cognitive impairment; FTD, frontotemporal dementia; n.s., not significant.
Values are mean z-scores (standard deviation). The p-values are from the Kruskal–Wallis tests with Monte Carlo method, the post-hoc comparisons
from the Man–Whitney U-tests.
aAll other comparisons are not significant.
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Figure 1 (A)Line charts of the cognitive dimension scores (with standarddeviations) comparedbetweenpatientswithmild cognitive impairment (MCI), Alzheimer’s
dementia (AD) and frontotemporal dementia (FTD) (in the standard battery) and between patients with aMCI, AD andmajor depression (in the challenging battery).
(B) Line charts of the cognitive dimension scores (with standard deviations) compared patients with stable MCI with patients with progressing MCI (*p< 0.01).
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memory dimensions (verbal learning and memory and
visual learning and memory) and the language dimension
(verbal language production). Furthermore, verbal learn-
ing and memory from the Challenging battery was the
single cognitive dimension that distinguished between
the patients with major depression and patients with
MCI. To distinguish between patients with MCI or AD
and patients with FTD, the language dimension (verbal
language production) and one of the executive function
dimensions (executive visual ability) showed the best
discriminability.
Further post-hoc analyses were made to test if the
cognitive dimensions are able to differentiate those
patients with MCI from the Memory Clinic study
sample (Table 2A) at greater risk of progressing from
MCI to dementia (progressing MCI) from those who
remain stable or regress to a cognitively healthy state
(stable MCI; Table 6. In both test batteries, results indi-
cated that progressing MCI showed significant worse
scores in the verbal learning andmemory dimension com-
pared with stable MCI patients (p< 0.001; Figure 1 (B)).
The difference in the observation periods between
progressingMCI and stableMCI is significant (p< 0.001).
Thus, the results with respect to this distinction must be
interpreted with great caution. To see if the different sub-
types of MCI patients (Table 2A) differ in their cognitive
dimension profiles, discriminant analyses were conducted.
We refer to the Supplementary Material for these results.
Discriminant analyses were conducted to calculate
the probability that a new patient is classified in the
correct diagnostic group based on the cognitive
dimension scores. The validation of correct classifica-
tion by means of the cognitive dimension scores
revealed that the cognitive dimension scores of the
standard battery were good in classifying MCI
(82.0%) and AD (83.0%) patients in the correct diag-
nosis group. In the challenging battery, the cognitive
dimension scores demonstrated a near-perfect perfor-
mance in classifying patients with MCI (99.2%) but
classified only 20.8% of AD patients correctly (all
others were classified as MCI subjects). No valid
statements can be made regarding the classification
of patients with FTD or with major depression as these
samples were too small.
Discussion
This study found seven-factor solutions in two slightly
different test batteries to reduce a variety of interre-
lated neuropsychological test results. The seven cogni-
tive dimensions found in both tests batteries were
verbal attention, visual attention, verbal learning and
memory, visual learning and memory, verbal language
production, executive motor ability and executive vi-
sual ability. On the basis of data from an independent
sample of normal control participants, it was possible
to create formulae with standard scores (z-score) for
each cognitive dimension. These formulae allow for
an easier characterization and interpretation of a
subject’s cognitive performance. Furthermore, the
comparison between the different diagnostic groups
showed that the cognitive dimensions in both test bat-
teries are able to separate patients with different forms
of dementia and patients with major depression. An
additional analysis revealed that the new dimension
scores were able to distinguish new samples of patients
with MCI from patients with AD with high accuracy.
These findings are in line with a number of other
studies examining the intrinsic structure of neuropsy-
chological test batteries with dementia patients that
also found five or more cognitive dimensions (e.g.,
Chapman et al., 2010a, 2010b; Dowling et al., 2010;
Ownby et al., 2004; refer also to Supplementary
Table). Looking at these different studies, the diver-
gent findings in factor solutions may be due to differ-
ent patient groups (i.e., MCI versus AD versus mixed
samples (refer to Siedlecki et al., 2008)), different
stages of dementia (mild versus advanced), different
kinds of statistical analyses (e.g., confirmatory versus
exploratory factor analysis versus principal component
analysis (Dowling et al., 2010)) or the different neuro-
psychological tests included in the batteries.
To our knowledge, this is the first study to provide
formulae to calculate z-scores for cognitive dimensions,
which can be used in clinical and research settings. We
Table 6 Demographic characteristics of the MCI subsample (n = 683)
Stable
MCI
Progressing
MCI
Standard battery
N 174 41
Age±SD (y) 72.1± 8.71 75.3± 5.34
Gender, males (%) 47.1 58.5
Time between baseline
and diagnosis ±SD (months)
6.17± 13.7 24.1± 14.8
(stable: MCI or NC;
progressive: dementia)
Challenging Battery
N 436 32
Age±SD (y) 65.1± 9.79 74.1± 6.07
Gender, males (%) 41.1 59.4
Time between baseline
and diagnosis ±SD (months)
8.65± 15.6 21.4±12.8
(stable: MCI or NC;
progressive: dementia)
SD, standard deviation; MCI, mild cognitive impairment; NC,
normal controls.
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found that these cognitive dimension z-scores from the
four diagnoses of interest (MCI, AD, FTD and major
depression) were able to significantly distinguish
between the different diagnostic groups (Table 5A
and 5B and Figure 1(A)) and that the dimension ver-
bal learning and memory can discriminate patients
with stable MCI from patients with progressing MCI
(Figure 1(B)). Furthermore, these cognitive dimen-
sions represent an elegant solution to practical issues
in the clinical and research environment. Compared
with the wide range of interrelated cognitive variables
or to a single summary score, they are more likely to
be able to show clinical courses of cognitive impair-
ments or treatment responses in specific cognitive
domains.
To validate these results, we tested the dimen-
sions in a new sample of patients and found that
the probability for a given patient to be categorized
as MCI or AD on the basis of the seven cognitive
dimensions was high in both test batteries. Regard-
ing patients with a FTD or with major depression,
there cannot be made any valid statement as the
samples of these patients were too small.
A limitation of the present study is that the
diagnostic accuracy of the cognitive dimensions
may be partially overestimated: The neuropsycho-
logical data used to calculate the dimension scores
were available to clinicians during the diagnostic
process. This partial circularity may have artificially
heightened the diagnostic accuracy of the cognitive
dimensions.
In the present study, we identified meaningful
and reliable dimensions of cognitive performance
and created z-scores for these dimensions in order
to produce a common metric among the dimen-
sions. Further analyses revealed that these cognitive
dimensions can separate between patients with dif-
ferent types of dementia and patients with major
depression and that the new dimension scores were
able to distinguish new samples of patients with
MCI from patients with AD with high accuracy.
These results demonstrate that the cognitive dimen-
sions are a useful neuropsychological diagnostic, as
the ability to define the latent structure minimizes
redundancy, increases the reliability of measures
and reduces the risk of type I error because of
multiple comparisons. The cognitive dimensions
found in this study allow clinicians to avoid
assuming a single test score represents a single
cognitive dimension and instead permit remapping
of a patient’s test battery results to fewer cognitive
dimension scores, thereby facilitating the interpre-
tation and communication of the results.
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